Jazz Pharmaceuticals shared on LinkedIn:
“November marks a pivotal moment in oncology as we observe both Gastric Cancer Awareness Month and Lung Cancer Awareness Month.
Though distinct, both diseases share an important reality: as cancer care evolves, patients need both meaningful treatment options and timely, understandable information to navigate the changing treatment landscape. From biomarker testing in gastric cancer to tailored resources for small cell lung cancer, accessible resources can help transform complex clinical information into actionable conversations with their healthcare teams.
Read more from Bob Redman, Vice President, Head of Solid Tumor, about why progress in cancer care matters most when it reaches patients, and our continued efforts to bring meaningful advances to people living with these diagnoses.”
About Gastric and Lung Cancer Awareness Month
November brings both Gastric Cancer Awareness Month and Lung Cancer Awareness Month, shining a light on two diseases that continue to affect millions of people worldwide. In 2024, around 1 million people were diagnosed with gastric cancer and 2.6 million with lung cancer. This month serves as a reminder of the importance of early diagnosis, biomarker testing, and ongoing research into new treatment options.
Jazz Pharmaceuticals is highlighting the need to make advances in cancer care more accessible to patients, whether through information about biomarker testing in gastric cancer or educational resources on small cell lung cancer. Helping patients and their families better understand the disease and available treatment options remains an important part of improving cancer care.
You may also be interested in: